Dirk Forstmeyer

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortés, David W. Cescon, Hope S. Rugo et al. · The Lancet · 2020 · 1.8K citations · Full text

Medicine, Oncology, Pharmacology +16

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

The performance of three oncogeriatric screening tools - G8, optimised G8 and CARG - in predicting chemotherapy-related toxicity in older patients with cancer. A prospective clinical study

David Kotzerke, F. Moritz, Luisa Mantovani et al. · Journal of Geriatric Oncology · 2019 · 30 citations

Medicine, Oncology, Cancer Drug Toxicity Management +16

Health Literacy in Adolescent and Young Adult Cancer Patients and Its Association with Health Outcomes

Diana Richter, Anja Mehnert, Dirk Forstmeyer et al. · Journal of Adolescent and Young Adult Oncology · 2019 · 27 citations

Public Health, Health Education, Oncology +13

Quantitative temporal and spatial distribution of adenovirus type 2 correlates with disease manifestations and organ failure during disseminated infection

Dirk Forstmeyer, Cornelia Henke‐Gendo, Verena Bröcker et al. · Journal of Medical Virology · 2007 · 25 citations

Life Sciences, Infectious Diseases, Microbiology +16